8-K: INmune Bio Amends Warrants, Lowers Exercise Price to $1.95

INmune Bio Inc. amended 1.35 million outstanding warrants, reducing the exercise price to $1.95 and extending their term to June 30, 2026, in exchange for $67,416.

Summary

• INmune Bio Inc. entered into a Warrant Amendment on December 22, 2025, with certain holders of its April 2024 warrants.
• The amendment applies to an aggregate of 1,348,315 outstanding April 2024 Warrants.
• The exercise price for these warrants was reduced to $1.95 per share, which is greater than the Nasdaq Minimum Price as of December 17, 2025.
• The term of these warrants was extended, with a new expiration date of June 30, 2026, replacing the previous term tied to a two-year anniversary or positive Phase 2 Alzheimer's program data.
• As consideration for the amendment, holders paid the company $0.05 per warrant, totaling aggregate proceeds of $67,416.

Sentiment

Score: 6

Explanation: The company secured immediate cash proceeds from the warrant amendment and extended the potential for future capital infusion through warrant exercises, albeit at a reduced exercise price. This is a mixed but generally managed capital event.

Positives

• The company received $67,416 in aggregate proceeds from the warrant holders for the amendment.
• The reduced exercise price of $1.95 remains above the Nasdaq Minimum Price, ensuring compliance with listing rules.
• Extending the warrant term provides holders with more time to exercise, potentially leading to future capital infusion if exercised.

Negatives

• The reduction in the exercise price to $1.95 means that if the warrants are exercised, the company will receive less capital per share compared to the original, higher exercise price.
• The extension of the warrant term could dilute existing shareholders if the warrants are exercised at a price below the market price at the time of exercise.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the new warrant expiration date. The amendment removes the previous expiration trigger tied to positive top-line data from the Phase 2 Alzheimer's program of XPro1595, making the warrant's term independent of this clinical milestone.

Industry Context

This specific warrant amendment is a company-specific capital structure adjustment and does not directly relate to broader industry trends or competitors, other than the general need for biotechnology companies to manage their capital and financing instruments.

Stakeholder Impact

• Shareholders: Potential for future dilution if warrants are exercised at $1.95, which could be below the market price at the time of exercise. However, the company received immediate cash.
• Warrant Holders: Benefit from a reduced exercise price and an extended exercise period, making their warrants more valuable or easier to exercise.

Next Steps

• Warrant holders have until June 30, 2026, to exercise their amended warrants at the new price of $1.95.

Key Dates

Recommendation

The warrant amendment provides a small immediate cash inflow and extends the potential for future capital, but at a lower exercise price, which could lead to dilution. This is a capital management event that does not fundamentally alter the company's operational outlook or core value proposition, suggesting a neutral 'hold' stance until more significant operational or financial news emerges.

Keywords

INmune Bio, INMB, Warrant Amendment, Exercise Price, Warrants, Capital Raise, Nasdaq, Biotechnology, Pharmaceuticals